CRMD

CorMedix Inc. Class Action: Current shareholders of CorMedix Inc. can pursue corporate reforms and recover funds after a court denied the defendants' motion to dismiss a securities fraud class action alleging false statements about the company's manufacturing process and FDA approval prospects.

Maison Solutions Inc. and Napco Security Technologies Class Actions: Shareholders of Maison Solutions Inc. and Napco Security Technologies are also eligible for corporate reforms and fund recovery as their respective securities fraud complaints survived motions to dismiss, citing misleading statements regarding business operations and financial disclosures.

AdaptHealth Corp. Class Action: A federal securities fraud class action against AdaptHealth Corp. has been stayed pending mediation, with allegations of improper billing practices and misleading statements to investors leading to inflated stock prices.

Other Companies' Class Actions: Similar shareholder class actions are ongoing for CorMedix Inc., Napco Security Technologies, and Virtu Financial Inc., with allegations of false disclosures and misleading statements affecting their stock performance, all allowing shareholders to seek corporate reforms and potential financial returns.

CorMedix Inc. Updates Guidance: CorMedix announced that a large dialysis organization has begun ordering its DefenCath catheter lock solution, leading to an increase in expected net sales for the second quarter from $31 million to a range of $35 million to $40 million.

Analyst Coverage and Stock Performance: HC Wainwright initiated coverage on CorMedix with a Buy rating and a price target of $20, citing strong initial results for DefenCath and potential for long-term revenue growth, while the company also priced a public offering expected to raise approximately $85 million.